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Summary
We have synthesized a series of phenothiazine deriva-
tives, which were used to test the structure-activity re-
lationship of binding to HIV-1 TAR RNA. Variations
from our initial compound, 2-acetylphenothiazine, fo-
cused on two moieties: ring substitutions and n-alkyl
substitutions. Binding characteristics were ascer-
tained via NMR, principally by saturation transfer
difference spectra of the ligand and imino proton res-
onance shifts of the RNA. Both ring and alkyl substitu-
tions manifested NMR changes upon binding. In gen-
eral, the active site, while somewhat flexible, has
regions that can be capitalized for increased binding
through van der Waals interactions and others that
can be optimized for solubility in subsequent stages
of development. However, binding can be nontrivially
enhanced several-fold through optimization of van
der Waals and hydrophilic sites of the scaffold.
Introduction
Synthesis and evaluation of focused libraries of small
molecules for binding to specific targets are crucial for
generating leads in the drug discovery process. During
the knowledge-based drug design process, repeated
cycles of synthesis and testing of smaller libraries while
optimizing for a desired specificity or affinity is an effi-
cient way to generate high-quality lead compounds [1,
2]. Although RNA is a potentially valuable drug target,
few compounds specifically targeting RNA are currently
on the market; some antibiotics in current clinical use
provide a precedent for targeting RNA since they bind
to conserved microbial rRNA structural motifs. One ad-
vantage of targeting RNA compared to developing
drugs against protein receptors is that it can open new
fronts in the fight against diseases [3].
According to World Health Organization estimates, 42
million people are living with HIV/AIDS worldwide. With
growing resistance of the retrovirus HIV-1 (human im-
munodeficiency virus, type 1) to current drugs, there is
need for research on other HIV-1 targets. The HIV-1 ge-
nomic RNA itself presents possibilities. One of the more
prominent RNA targets is the HIV-1 TAR RNA motif,
which plays an important role in the life cycle of HIV [4,
5]. Use of a selective inhibitor that blocks the interaction
of TAR and the virus-encoded protein Tat, which regu-
*Correspondence: james@picasso.ucsf.edulates RNA transcriptase processivity, is one possible
way of keeping the virus from proliferating [6]. A number
of recent studies have identified small-molecule ligands
that bind to TAR RNA, thus inhibiting Tat binding or Tat
transactivation [7–10].
We have previously identified a series of ‘‘hits,’’ i.e.,
compounds that specifically bind HIV-1 TAR RNA, by
using a sequential combination of virtual screening fol-
lowed by limited experimental screening [7]. Some of
these hits belong to a class of compounds called pheno-
thiazines, which have been used as antipsychotic
agents for many years. Besides its proven high bioavail-
ability and low toxicity, relative to other RNA binding
drugs, phenothiazine is an attractive scaffold for poten-
tial lead development due to its low molecular weight
and single positive charge, which afford ample room to
build in enhanced binding affinity.
By testing a small set of commercially available pheno-
thiazines against the TAR RNA structure, we were able to
establish that this class of compounds is an interesting
scaffold for further derivatization [11]. NMR is especially
useful at this stage of the optimization process because
the tested compounds do not yet have a high affinity,
thus requiring methods that are able to identify and clas-
sify weak interactions. NMR is also quite robust in that
no false positives or negatives are found in NMR screen-
ing, where a hit is defined as a small molecule interacting
specifically with the active site of the biomolecule. NMR
also allows us to determine the affinity and specificity of
the small molecules tested by monitoring imino proton
chemical shifts of the RNA target [12, 13]. Differential line
broadening (DLB)hasbeenusedfor manyyears to identify
ligand moieties involved in binding interactions [14]. Simi-
larly, saturation transfer difference (STD) NMR has proven
to be efficient in identifying and characterizing weakly
binding compounds even to small RNA constructs [15].
The initial testing of commercial phenothiazines
showed that substitutions around the phenothiazine
ring and the presence of a basic amine functionality
were important structural features for binding activity
[11]. An NMR structure of acetylpromazine complexed
with the HIV-1 TAR RNA construct has also been solved
in our lab [16], and we used this structure to illuminate
the SAR data obtained (Figure 1). The same 27 nt RNA
construct used in structural elucidation of the acetylpro-
mazine TAR RNA complex is utilized for the binding
studies reported here. The objective was to generate
derivatives of the known ligand basic phenothiazine
scaffold in order to ascertain some aspects of a struc-
ture-activity relationship. To identify the crucial binding
interactions of the original scaffold, two libraries were
designed: the first one to probe substitutions of the phe-
nothiazine ring system, and the second one to probe
aliphatic side chain substitutions.
Results and Discussion
Chemistry
We set out to evaluate structure-activity relationships
for binding of a series of compounds with the
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994Figure 1. Binding Site of TAR RNA with Ace-
tylpromazine Bound
See Compound 6 in Figure 3. The NMR
structure has PDB code 1LVJ [16].
(A) Perspective of the phenothiazine scaffold
from the minor groove.
(B) Perspective of the phenothiazine scaffold
from the major groove.
(C) Perspective of the entire compound. The
second half of RNA was removed for visual-
ization purposes.phenothiazine scaffold to TAR RNA. A concomitant goal
was to explore the ability to moderate the potency of the
commercially available compounds already tested. We
dissected the scaffold into two parts: substitutions of
the phenothiazine rings and substitution of the n-alkyl
linker variations. We proceeded to synthesize chemical
libraries with modifications in each of those moieties.
The phenothiazine ring system was constructed from
diarylamine starting materials by an iodine-catalyzed re-
action with sulfur [17]. We performed many variations of
this reaction in an attempt to improve the generally low
yields and found significant improvement by conducting
the cyclization with microwave irradiation. While micro-
wave conditions have been briefly described before for
the synthesis of phenothiazines, they relied upon the
use of strong acid or Lewis acid catalysts or the use of
dry conditions [18, 19]. Under our optimized conditions,
the reaction is carried out in water in a sealed reaction
vessel and is heated to 190C for 20 min under micro-
wave irradiation (Figure 2A, Compounds 1 and 2). This
method was very convenient, since the hydrophobic
product immediately precipitated upon cooling and
could easily be purified by filtration. This new, to our
knowledge, method for the synthesis of phenothiazines
was successfully used to synthesize a set of new
substituted 10H-phenothiazines (Figure 2A, Compound
2). The 10H-phenothiazines were then alkylated by using
sodium hydride and 1-chloro-3-iodopropane (or appro-
priate chloroiodoalkane) to give the chloroalkylpheno-
thiazine (Figure 2A, Compound 3). This intermediate
could then be aminated with dimethylamine (or another
secondary amine) in a sealed vessel with microwave ir-
radiation to afford the ring-substituted phenothiazine li-
brary (Figure 2A, Compound 4). The subset of these
compounds that were soluble and stable enough to be
tested for binding by NMR is reported in Figure 3.
For evaluation of side chain substituents, we decided
to fix the ring scaffold as 2-acetylphenothiazine and 2-
chlorophenothiazine and to vary the length of the alkyl
linkers and the substituents on the basic amine group
(Figure 2B). We again alkylated the 10H-phenothiazine
ring by using sodium hydride and four chloroiodo alkyl
chains, the length of which varied from 3 to 6 methylene
units (Figure 2B, Compounds 5–7). We found that the re-sulting alkyl chloride intermediate was not sufficiently
reactive to yield product with a diverse set of amines,
so we used the Finkelstein reaction to convert the chlor-
oalkane to an iodoalkane (Figure 2B, Compound 8). The
iodoalkane intermediate then could be reacted with a di-
verse set of primary and secondary amines to afford the
completed side chain variation library (Figure 2B, Com-
pound 9). In general, these reactions proceeded quite
cleanly, with the major side reaction being the elimina-
tion of the iodide in longer linkers. For this set, those
compounds soluble and stable enough to be tested by
NMR are reported in Figure 4.
Library Screening
STD NMR experiments and differential line broadening
(DLB) of proton resonances on the ligand enabled as-
sessment of ligand binding to the RNA target [12, 14,
15]. RNA imino proton chemical shifts were monitored
to identify and characterize the location of small-mole-
cule binding to the 27 nt construct of HIV-1 TAR RNA.
Only stable, water-soluble compounds were utilized
for these studies.
The affinities of the compounds for the RNA construct
were divided into three categories by a combination of
DLB and STD effects. For binders deemed more promis-
ing by ligand NMR results, RNA imino proton chemical
shift measurements were also carried out. We were
able to classify 24 compounds according to their RNA
binding interactions manifest in resonance line broaden-
ing and STD spectral intensities. Figure 5 shows refer-
ence and STD spectra of two selected compounds
from the libraries. Compound 17 exhibited strong line
broadening effects and substantial STD enhancements
(Figure 5A). Compounds with these characteristics
were categorized as strong binders. On the other
hand, Compound 23 shows only weak broadening of
the aromatic protons, at similar ligand and RNA concen-
trations as for Compound 17 (Figure 5B). Compounds
showing these characteristics were categorized as
weak binders.
Nine compounds were examined to determine the ef-
fects of aromatic ring substitutions on binding affinity
(Figure 3). For analysis, we divided the substituents by
location on the ring system (see Figure 1 for numbering).
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ring system requires us to consider whether a substitu-
ent is exerting its influence on the minor groove or major
groove side of the complex. Bond rotation around the
linker-N-to-alkyl-C bond will enable almost the same
conformation in the complex. As shown in Figure 1, we
have found that a hydrophilic group at position 7 (or 3)
will be exposed to solvent on the minor groove side of
the complex. That being said, TAR RNA has been shown
to be extremely flexible in solution, and portions of the
active site can potentially distort to accommodate par-
ticular substituents [10, 16, 20–22].
In Figure 3A, we examine the effect of adding methyl
groups. In Compound 2, the methyl group is in position
2 on the ring scaffold. If a substituent in this position is
oriented toward the major groove side of the binding
pocket, as in position 6, it will sustain some amount of
van der Waals (VDW) clash. Therefore, we expect that
the methyl orientation is toward the minor groove, mak-
ing room for the single methyl substituent. The double
methyl substituent supports this hypothesis with re-
Figure 2. Synthesis of a 10H-Phenothiazine Library
For more information, see Experimental Procedures (‘‘Synthesis of
Compounds’’) and Results and Discussion (‘‘Chemistry’’).
(A) Ring variant syntheses. The conditions for syntheses are: (A) 2
eq. S8, catalyst I2, water, 50 W microwave, 190
C, 20 min; (B) 1.2
eq. NaH, DMF, 0C, 1 hr; (C) 5 eq. Cl(CH2)3I (slow reverse addition),
RT, 1 hr; (D) 4 eq. dimethylamine (8{1}), 2M THF, DMF, 30 W micro-
wave, 100C, 40 min.
(B) Side chain variations. The conditions for syntheses are: (A) 2.1
eq. NaH, THF, DMSO; (B) 3 eq. Cl(CH2)nI, (6a–6d), reverse add.,
THF, DMSO, RT, 2 hr; (C) 5 eq. KI, 2-methyl-4-propanone, 130C,
reflux, 40 hr; (D) 2 eq. HNR1R2, DMF, 60C, 20 hr.duced binding affinity, which we attribute to VDW clash
from the second methyl group, which must be on the
major groove side.
In Figures 3B–3D, we have ranked the compounds by
hydrophicility. In Figure 3B, substituents in position 1
are solvent exposed but could also pack with the top
portion of the binding site. This orientation rationalizes
the improved binding for the more hydrophilic hydroxyl
substituent as well as the additional increase in affinity
from VDW interactions with the methoxy substituent.
The carbon at position 7 in Figure 3C is completely sol-
vent exposed. Therefore, we propose that increasing
hydrophilicity of the substituent in this position im-
proves binding in the series. Finally, the carbon 3 posi-
tion is completely buried. Therefore, the more hydro-
phobic compounds in Figure 3D still have reasonable
binding. The methoxyl substituent has reduced binding
in the series due to VDW clashes in the major groove
orientation.
For the side chain-substituted library, the ratio of the
STD intensities of the aromatic region resonances ver-
sus the aliphatic region resonances and line broadening
were used to rank the small library of compounds. From
analysis of the STD spectra of the originally discovered
ligand acetylpromazine, we knew that the aromatic rings
of the heterotricyclic structure have a closer interaction
with the RNA protons than the aliphatic side chain [11].
This is not apparent in the NMR structure of acetylpro-
mazine in complex with TAR RNA, where the side chain
and ring system of the ligand appear to be equally inter-
active with the RNA [16]. As discussed previously [11],
we believe that this apparent discrepancy may be due
to the fact that we are pinning down the relatively flexible
side chain in the structure calculation by intermolecular
NOEs, whereas that particular conformation with the
side chain pinned down in the minor groove may repre-
sent less than half of the population of the ligand in the
bound form. The weaker STD intensities of the side
chain implied that optimization of that region of the li-
gand would be beneficial. Phenothiazine derivatives
with stronger STD intensities in the aliphatic side chain
may reflect a larger population of bound ligand with
the side chain immobilized in the minor groove.
For the side chain variation series, the relative STD en-
hancements of the aromatic protons were larger than
those of the side chains, providing strong evidence
that it is the phenothiazine ring that provides much of
the binding energy. However, in the substituent compar-
ison, the phenothiazine ring system remained the same
within each series. Therefore, it was possible to corre-
late stronger aliphatic STD enhancements with higher
affinity of the ligands because the phenothiazine re-
mained largely unchanged. In addition, stronger relative
STD signals of the aliphatic groups were reflected in
stronger DLB effects. Detailed epitope mapping of the li-
gands was not performed due to significant overlap in
some cases, especially of the aromatic protons.
The qualitative binding affinities for the side chain var-
iations can be found in Figure 4. In the solved structure,
the minor groove portion of the lower half of the binding
site is largely comprised of an unpaired cytosine from
the loop region of the RNA. This cytosine closes over
the ligand situated at the binding site; in fact, the ligand
cannot get into the structure determined without the
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996Figure 3. Binding between Phenothiazine Ring Derivatives and TAR RNA
(A–D) Binding was classified into three binding categories: affinities ofw0.1–1 mM (+++), affinities ofw1–5 mM (++), and affinities weaker than
w5 mM (+). For all panels, the compounds are at a concentration of 500 mM and the RNA is at a concentration of 50 mM. Compounds are
separated from left to right by the location of substituents on the rings and are roughly ordered from top to bottom by increasing hydrophilicity.bulge cytosine being moved aside. While this cytosine is
within hydrogen bonding distance of the ribose of the
following nucleotide, we hypothesize that this portion
of the binding site is somewhat malleable and thus
able to accommodate larger groups on the side chain re-
gion. For the acetylphenothiazine scaffold derivatives inFigure 4A, we suggest that the cyclohexyl structure is in-
trinsically stable enough to deform the active site when
combined with additional VDW interactions. Compound
14, however, has a bit too much bulk for the active site as
well as significant entropy loss upon binding, resulting in
a decrease in binding. For the remaining compounds inFigure 4. Phenothiazine Scaffolds with Side Chain Substitutions Tested for Binding to TAR RNA
(A and B) As explained in the Results and Discussion (‘‘Library Screening’’), the chlorine substituent causes the ring system to flip in orientation
from the structure in Figure 1. As a result, affinity comparisons can only be made within a particular column. Binding categories and
experimental conditions same as for Figure 3.
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VDW clash, but too much internal flexibility to distort the
active site. In addition, because these compounds are
so flexible, the entropic penalty to bind these molecules
must be higher than the enthalpic gain.
For the choro-substituted phenothiazines in Fig-
ure 4B, the side chain will be in a slightly different orien-
tation in response to the flipped scaffold (relative to the
acetylphenothiazine series); thus, this series cannot be
directly compared to that in Figure 4A. However, many
of the same conclusions can be drawn. For Compounds
17 and 18, the single substituents have a thinner diame-
Figure 5. Representative NMR Spectra of Phenothiazine Com-
pounds from Figure 4
For all spectra, the compound is at a concentration of 500 mM and
the RNA is at a concentration of 50 mM.
(A) Compound 17: (1) Reference spectrum of compound alone; an
asterisk indicates impurities. (2) Reference spectrum of compound
in the presence of TAR RNA showing considerable line broadening
induced by the oligonucleotide. (3) STD NMR spectrum of the com-
pound in the presence of TAR RNA. The RNA is irradiated at 5.8
ppm, as indicated in the figure by the arrow. Signals of Compound
17 indicating the binding interaction are clearly visible, while those
of the impurities indicated by asterisks are subtracted. RNA signals
are also visible because the molecular size is not large enough to
eliminate the background signals by a relaxation filter.
(B) Compound 23: (1) Reference spectrum of compound alone. (2)
Reference spectrum of the compound in the presence of TAR
RNA showing a small amount of line broadening localized to the ar-
omatic ring protons. (3) STD NMR spectrum of the compound in the
presence of TAR RNA. The RNA is irradiated at 5.8 ppm, as indi-
cated in the figure by the arrow. In this case, signals for the aro-
matic protons manifest an effect, while the side chain and the im-
idazole group are subtracted.ter than the original dimethyl substituents, which we hy-
pothesize enables these flexible chains to adapt to the
minor groove. The two cyclohexyl compounds most
likely have the same effect as what is shown in Figure 4A;
they are intrinsically stable enough to deform the active
site while compensating with additional VDW packing.
The cyclopentyl rings have a shorter chain length than
any other substituent in the series. Because the active
site does not widen until a bit further down, these sub-
stituents are likely disrupting the upper portion of the ac-
tive site. Finally, for both of the aromatic compounds,
the stacking interactions with bases are not possible
without significant rearrangement of the TAR structure,
resulting in entropic loss of binding. In this case, the
substituents would be solvent exposed, thus explaining
their reduced binding.
For compounds that showed large STD intensities and
exchange broadening effects, the RNA imino proton res-
onances were monitored. Imino proton chemical shift
changes upon addition of ligand provide information
about the binding site on the RNA and also permit KD
values to be determined (Figure 6). For Compound 11,
the most potent of the tested molecules, the calculated
KD value was 140 mM, or about twice that of the original
ligand, acetylpromazine [11]. As shown for Compound
11 with the 3-hydroxymethylpiperidine ring (see Fig-
ure 7), the imino resonance that shifts most upon
Figure 6. Binding Affinities as Determined by Chemical Shift
Monitoring of TAR RNA Imino Proton Resonances for Selected
Compounds
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Spectra of RNA in the Presence of Com-
pound 11 from Figure 4
For all spectra, the RNA is at a concentration
of 50 mM.
(A) Sequence of the TAR RNA construct
used for testing the phenothiazine deriva-
tives.
(B) Chemical shift monitoring of TAR RNA
imino proton resonances upon addition of
Compound 11 in increasing concentrations,
from 0 to 500 mM. The chemical shift differ-
ence is plotted against the compound con-
centration to determine the dissociation con-
stant of the TAR-ligand complex.addition of the ligand is that of G26 of the HIV-1 TAR
RNA. The imino proton resonance of G26 exhibits a large
upfield shift due to ring current effects from the stacked
ligand benzene I. As with Compound 11, the other li-
gands exhibited imino chemical shifts only for residues
in the vicinity of the TAR bulge. It should also be noted
that there was no evidence that more than one of the
tested ligands binds to the RNA at the same time, as
no significant imino chemical shifts were observed out-
side of the binding site for any of the tested compounds.
From previous studies, which entailed several different
kinds of multinuclear and multidimensional NMR spec-
tra, we also found that only residues in the vicinity of
the bulge experienced changes upon ligand binding,
and that there were no changes evident for other resi-
dues upon addition of a large excess of ligand [7, 16].
We would like to emphasize that a well-defined SAR
cannot be expected from compounds with binding affin-
ities in this range. However, the SAR performed for the
focused library of phenothiazines suggests a few ave-
nues for future developments. A side chain with 3–4
methylenes between the ring and the heteroatom seems
optimal (Figure 4). Consistent with the NMR structure,
a flexible linear chain will snake nicely along the minor
groove. In addition to VDW interactions, heteroatoms
or functional groups with hydrogen bonding capabilities
may improve binding. Some rigidity in the side chain will
decrease entropic loss upon binding, but the orientation
and nature of further derivitization will become more
critical. Ring substituents may further enhance binding,
and extension beyond the methoxyl group in position 1
should gain additional VDW interactions. The results of
Figure 3 also imply that it might be of value to have a phe-
nothiazine with a hydrophilic substituent in position 7
and a small hydrophobic substituent in position 3. These
implications from the SAR are entirely consonant with
the structure.
Significance
The synthesis of the focused library of phenothiazine
derivatives—a class of nontoxic, bioavailable RNA
binders—and analysis of the SAR for binding toHIV-1 TAR RNA reported here are important exten-
sions of earlier work. The study explores structural
features affecting phenothiazine interactions with
TAR RNA. The observation that both moieties varied
here—ring substituents and the n-alkyl substitu-
tions—affect binding agrees with our published struc-
ture of TAR with acetylpromazine. In addition, the re-
sults described above suggest that the binding site,
while flexible, has regions that restrict growth. There
are also several areas of the binding site that are sol-
vent exposed, which can be exploited in later stages
of development.
The most significant factor in the data is that com-
pounds possessing a four-atom linker between the tri-
cycle and the distal base are among the tightest
binders. In the pharmacological literature, neuroleptic
activity is strongly associated with a three-atom linker,
and antihistamine activity is associated with a two- or
three-carbon linker. Obviously, any RNA binding com-
pound would require the ability to dissociate these un-
desirable activities from therapeutic effects. Com-
pounds with longer linkers provide an attractive
potential route toward that goal.
In future work, knowledge gained in this study can
guide further enhancement of specificity. The pheno-
thiazines studied have a single positive charge and rel-
atively low molecular weight. In addition to modifica-
tions studied here, increased affinity may be gained
by combining the appropriate substituted phenothia-
zine with other groups known to enhance RNA binding
(e.g., amino sugars, guanidino groups, and intercalat-
ing groups). However, as shown here, binding affinity
can be improved through optimization of VDW and hy-
drophilic sites of the scaffold. This hypothesis is sup-
ported by the increase in binding from the naked pro-
mazine scaffold to the final product from this study,
which have binding affinities of 5 mM and 140 mM,
respectively.
Experimental Procedures
NMR Experiments
Unlabeled RNA samples were prepared and purified as previously
described [11]. NMR experiments were performed on a Varian Inova
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999600 MHz spectrometer. Typically, a spectrum of the compound
alone at a 250 or 500 mM concentration was acquired, and then
RNA was added from a concentrated stock solution to produce
a 25 or 50 mM final RNA concentration. Reference and STD spectra
were compared. STD NMR spectra were acquired by internal sub-
traction via phase cycling. On-resonance irradiation was set to 5.8
ppm, and off-resonance irradiation was set to w30 ppm where no
RNA resonances are present. Typically, 256 scans were acquired
for the STD experiments. Presaturation of RNA resonances was
achieved by an appropriate number of band-selective G4 Gaussian
cascade pulses to give a saturation time of 2 s. The temperature was
set to 15C in all STD experiments. 1D-NMR imino proton spectra
were acquired by using hard-pulse WATERGATE water suppres-
sion, and the excitation profile was optimized for maximum intensity
at 13 ppm.
For the qualitative ranking of compound binding affinities, spectra
of resonances from the ligand alone were compared with the same
resonances in STD spectra acquired with ligand in the presence of
RNA (see Figure 5 for representative examples). A classification of
binding was made according to observed STD intensities and line
broadening effects (Figures 3 and 4).
For a select subset of derivatives, dissociation constant (KD)
values were determined by titrating the RNA with ligand and moni-
toring the RNA imino proton chemical shift differences (Figure 6).
Typically, five titration points were taken for each compound for
which we determined the KD. In a previous study, the first compound
of this series, acetylpromazine, was found to have a binding affinity
of 270 mM [11]. The qualitative study described above found the re-
maining compounds to be in the same binding range of w0.1–1.0
mM. Substantial line broadening observed for some of the tested
compounds stems mostly from the broadening of resonances due
to chemical exchange of the ligand either between free and bound
species or, more likely, from multiple conformations on the RNA;
the latter may result from the symmetry of the ligand binding in a sim-
ilar fashion, but with the ring flipping 180. Except for the parent
compound listed for comparison, for the compounds whose KD
values were determined (Figure 6), the symmetry was broken such
that one orientation of binding was strongly preferred; this was
clearly evident in the quality of the various spectra (primarily line-
shapes) acquired for these complexes compared with the others.
For these three compounds, it appears that fast-exchange condi-
tions were obtained. As noted already, our NMR results indicate
that these ligands bind to only a single site on our TAR RNA con-
struct. The equation for single-site binding under the fast-exchange
regime,
KD = CL

d2 dF
dB2 d

; (1)
was used to obtain KDs as chemical shifts were observed for the
complex (d), as a function of the concentration of the ligand (CL), rel-
ative to the chemical shifts for free RNA (dF) and ligand bound RNA
(dB) [23].
Synthesis of Compounds
All reagents and starting materials were purchased from commercial
sources and were used without further purification; solvents were
anhydrous HPLC grade. All parallel synthesis steps were carried
out in polypropylene fritted reaction tubes with the Bohdan Mini-
block 48-position reaction blocks. Microwave reactions were done
in a CEM Discover microwave reactor system. The reaction schemes
described below can be seen in Figure 2.
General Procedure for the Preparation of Substituted
10H-Phenothiazines
Each diphenylamine (Figure 2A, Compound 1) (2.0 mmol) was sealed
in a microwave reaction vessel with sulfur (128 mg, 4.0 mmol), a crys-
tal of iodine, and 2.5 ml doubly distilled water. The vessels were
heated to 190C for 20 min and then cooled to room temperature.
The crude mixture was extracted with 10 ml ethyl acetate and then
purified by column chromatography (silica gel; 90% ethyl acetate,
10% hexanes) to give the substituted 10H-phenothiazine product
(Figure 2A, Compound 2) (5%–45% yield).
General Procedure for the Alkylation of 10H-Phenothiazines
Sodium hydride (0.06 mmol) was added slowly at 0C to each stirring
solution of 10H-phenothiazine (Figure 2A, Compound 2) (0.05 mmol)dissolved in DMF (10 ml). The reaction was stirred for 30 min, and
was then allowed to warm to room temperature. This solution was
then added dropwise into a stirring solution of 1-chloro-3-iodopro-
pane (27 ml, 0.25 mmol) in DMF and was stirred for 1 hr. The reaction
mixture was extracted from a brine solution with ethyl acetate (25 ml,
33) and was then evaporated under reduced pressure. The crude
product was purified by column chromatography (silica gel; 90%
ethyl acetate, 10% hexanes) to give the substituted 10H-phenothia-
zine product (Figure 2A, Compound 3) (35%–85% yield).
General Procedure for the Amination of
10-(3-Iodopropyl)-Phenothiazines
Dimethylamine (4 eq., 40 ml of a 2 M solution in THF) was added to
each member of the substituted 10H-phenothiazine product
(Figure 2A, Compound 3) (0.02 mmol) dissolved in 1 ml DMF. The
mixture was sealed into a microwave reaction vessel and was
heated at 100C for 40 min. The crude reaction mixture was then pu-
rified by silica gel prep-TLC by using a 94.9:5:0.1 ratio of dichlorome-
thane:methanol:triethylamine. Pure products (Figure 2A, Compound
4) were isolated in 60%–85% yields.
General Procedure for the Alkylation of (2-Chloro or 2-Acetyl)-
10H-Phenothiazines
Sodium hydride (21 mmol, 60% dispersion in mineral oil) was slowly
added to a mixture of 2-chloro- or 2-acetyl- 10H-phenothiazine (Fig-
ure 2B, Compound 5) (10 mmol) stirring in a 1:1 solution of
DMSO:THF at 0C. The mixture was allowed to warm to 25C and
was then added to a stirring solution of iodochloroalkanes (Fig-
ure 2B, Compounds 6a–6d) (30 mmol) in N,N-dimethylformamide
(20 ml). The reaction mixture was stirred at room temperature for 2
hr, and 100 ml brine was added to stop the reaction. The crude prod-
uct was extracted into ethyl acetate (33, 20 ml) and then purified by
column chromatography (silica gel; 90% ethyl acetate, 10% hex-
anes) to give the title compounds (Figure 2B, Compound 7) in
40%–80% yield.
General Procedure for the Iodo Halogen Exchange Reaction
A mixture of potassium iodide (5 re, 5 mmol) and each member of the
alkylated (2-chloro or 2-acetyl-)10H-phenothiazines (Figure 2B,
Compound 7) (1 mmol) was heated until reflux in 2-methyl-4-propa-
none until the reaction had reached completion as determined by
NMR (about 3 days). The solvent was removed under vacuum, and
the product (Figure 2B, Compound 8) (95% yield) was used without
any further purification.
General Procedure for the Amination Diversity Step
Each iodoalkane intermediate (Figure 2B, Compound 8) (0.33 mmol)
was dissolved with N,N-dimethylformamide (5 ml) and divided into
five portions (0.06 mmol each). Each portion was mixed with
0.13 mmol n-butylamine, benzylamine, 2-aminoethanol, piperidine,
and imidazole. The crude reaction mixtures were worked up by ex-
tracting into methylene chloride (40 ml) from a 10% NaOH solution
(40 ml). Solvent was removed under vacuum, and each compound
was then purified by silica gel prep-TLC by using a 94.9:5:0.1 ratio
of dichloromethane:methanol:triethylamine. Pure products (Fig-
ure 2B, Compound 9) were isolated in 60%–85% yields.
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